自营业务方面，药师帮在药品审核环节实行总部质量管理部门、子公司质量管理员以及质量负责人的三 重审核制度。通过自行研发的线上系统实施全流程药品追溯管理，覆盖药品的采购、收货、验收、储 存、复核、销售及退货等环节，详尽记录药品的流通路径，并包含药品流向的终端药店和诊所信息。通 过这种全链路的数据追溯机制，确保了每一盒药品在流通过程中的关键信息得以记录，保障药品可追溯 性。 药师帮生态圈已成为院外医药行业的重要组成部分。截至2024年，药师帮平台入驻1.5万个上游商家， 注册药店用户49.1万家，基层医疗机构33万家，覆盖全国98.9%的县域及91.2%的乡镇；月均可售SKU达 390万个，月均活跃买家达43.3万家，每付费买家月均下单28.5次。 药师帮表示，自成立以来，药师帮始终坚持合规经营，积极落实平台主体责任，营造合规、安全、高效 的院外医药生态圈。ESG报告显示，药师帮已建立起完善的产品安全与质量审核制度。公司依据医药行 业相关的法律法规，制定了《药师帮平台采购用户注册审核制度》《商家入驻平台资质要求及审核标 准》《药师帮平台商家管理办法》等一系列管理制度。 平台业务方面，药师帮构建了全方位的商品质量管控 ...

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the report indicates a positive outlook based on financial performance and growth projections [1]. Core Insights - The company achieved a revenue of 17.904 billion yuan in 2024, representing a year-over-year growth of 5%. The adjusted net profit reached 157 million yuan, marking a 20% increase year-over-year, and the company declared a dividend of 0.075 yuan per share, with a payout ratio of approximately 170% [2][4]. - The self-owned brand business showed significant growth, with a monthly active buyer increase of 18%. The self-operated revenue for 2024 was approximately 16.973 billion yuan, accounting for about 95% of total revenue, with a notable 220% increase in the transaction scale of self-owned brand products [4]. - The company successfully turned a profit in 2024, with a cash flow cycle of approximately -32 days, indicating high cash turnover and efficiency. The operating cash inflow was 656 million yuan, a 45% increase year-over-year [4][5]. Financial Performance Summary - **2024 Financials**: Total revenue was 17.904 billion yuan, with a net profit of 30 million yuan. The gross margin was 10.13%, and the return on equity (ROE) was 1.29% [6][8]. - **2025-2027 Projections**: Expected revenues are 20.813 billion yuan in 2025, 23.476 billion yuan in 2026, and 26.494 billion yuan in 2027, with corresponding net profits projected at 129 million yuan, 274 million yuan, and 441 million yuan, reflecting significant growth rates [6][9]. - **Valuation Metrics**: The projected price-to-earnings (P/E) ratios for 2025, 2026, and 2027 are approximately 40.65, 19.12, and 11.90, respectively, indicating a favorable valuation trend as earnings grow [6][9].

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the report indicates a positive outlook based on financial performance and growth projections [1]. Core Insights - The company achieved a revenue of 17.904 billion yuan in 2024, representing a year-over-year growth of 5%. The adjusted net profit reached 157 million yuan, marking a 20% increase year-over-year, and the company declared a dividend of 0.075 yuan per share, with a payout ratio of approximately 170% [2][4]. - The self-owned brand business showed significant growth, with a monthly active buyer increase of 18%. The self-operated revenue for 2024 was approximately 16.973 billion yuan, accounting for about 95% of total revenue, with a notable 220% increase in the transaction scale of self-owned brand products [4][5]. - The company successfully turned a profit in 2024, with a cash flow cycle of approximately -32 days, indicating high cash turnover and efficiency. The operating cash inflow was 656 million yuan, a 45% increase year-over-year [4][5]. Financial Performance Summary - **2024 Financials**: Total revenue was 17.904 billion yuan, with a net profit of 30 million yuan. The gross margin was 10.13%, and the return on equity (ROE) was 1.29% [6][8]. - **2025-2027 Projections**: Expected revenues for 2025, 2026, and 2027 are approximately 20.813 billion yuan, 23.476 billion yuan, and 26.494 billion yuan, respectively, with year-over-year growth rates of 16%, 13%, and 13%. The projected net profits for the same years are 129 million yuan, 274 million yuan, and 441 million yuan, with significant growth rates of 330%, 113%, and 61% [6][8]. - **Valuation Metrics**: The projected price-to-earnings (P/E) ratios for 2025, 2026, and 2027 are approximately 40.65, 19.12, and 11.90, respectively, indicating a favorable valuation trend as earnings grow [6][8].

Core Insights - The company reported a significant increase in annual net profit, achieving a profit of 30.01 million yuan, marking its first full-year profit turnaround [1][2] - Adjusted net profit reached approximately 157 million yuan, reflecting a year-on-year growth of 20.1% [1][2] Revenue Growth - The company generated total revenue of approximately 17.904 billion yuan, representing a year-on-year increase of 5.5%, which is notably higher than the industry average growth rate [1] - Revenue from self-operated business grew by 5.8%, with a gross margin improvement to 6.2% [1] - Platform business revenue increased by 0.9%, with a gross margin enhancement to 83.4% [1] User Engagement - As of December 2024, the company had over 827,000 registered buyers, covering 98.9% of counties and 91.2% of townships nationwide [1] - The average monthly active buyers reached 433,000, with a payment rate of 92.7% [1] - Each paying buyer placed an average of 28.5 orders per month, indicating strong user engagement and loyalty [1] Cash Flow and Operational Efficiency - The company maintained positive operating cash flow of 656 million yuan, reflecting a year-on-year increase of 45% [2] - These financial metrics demonstrate the company's ability to leverage scale effects and maintain robust growth through economic cycles [2]

| 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 藥師幫股份有限公司 | | 股份代號 | 09885 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2024年12月31日止年度的末期股息 | | 公告日期 | 2025年3月17日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2024年12月31日 | | 宣派股息的報告期末 | 2024年12月31日 | | 宣派股息 | 每 股 0.075 RMB | | 股東批准日期 | 2025年5月21日 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 每 股 0.081 HKD | | 匯率 | 1 RMB : 1.083 HKD | | ...

Financial Performance - Total revenue for the year ended December 31, 2024, reached RMB 17,903,608, representing a 5.5% increase from RMB 16,972,276 in 2023[5]. - Adjusted net profit for the year was RMB 156,734, a 20.1% increase compared to RMB 130,542 in the previous year[5]. - Gross profit for the year was RMB 1,813,451, reflecting a 4.2% increase from RMB 1,740,923 in 2023[5]. - The net profit for the year ended December 31, 2024, was RMB 15.1 million, a significant recovery from a loss of RMB 3,206.5 million for the year ended December 31, 2023, marking the first profitable year for the company[82]. - The adjusted net profit margin for the year ended December 31, 2024, was 0.9%, compared to 0.8% for the year ended December 31, 2023[88]. - The company's sales cost rose by 5.6% to RMB 16,090.2 million for the year ending December 31, 2024, compared to RMB 15,231.4 million for the year ending December 31, 2023, mainly due to increased sales in the self-operated business[70]. - The gross margin for the self-operated business improved from 6.1% to 6.2% due to a higher proportion of exclusive strategic partnerships and proprietary brands in the product line[73]. - The company reported a significant decrease in other business revenue, dropping 21.1% to RMB 49.6 million for the year ending December 31, 2024, from RMB 62.9 million for the year ending December 31, 2023, due to adjustments in the operational/service model of spectral cloud testing[69]. User Engagement and Market Reach - The number of downstream users served exceeded 820,000, providing comprehensive digital solutions[8]. - As of December 31, 2024, the cumulative registered buyers exceeded 827,000, including 491,000 pharmacies and 330,000 primary medical institutions[23]. - The average monthly active buyers reached 433,000, representing an 18.0% year-over-year growth, while the average monthly paying buyers were 401,000, up 17.2% year-over-year[23]. - The average order number per paying buyer was approximately 28.5 orders per month[23]. - The platform's average SKU count increased to over 3,900,000, fulfilling diverse customer needs[26]. Product and Service Development - The platform's non-pharmaceutical product SKU count increased by approximately 50% during the reporting period[11]. - The company successfully onboarded around 600 traditional Chinese medicine manufacturers, enhancing product quality from the supply chain[11]. - The exclusive strategic partnership and proprietary brand products saw SKU growth of approximately 700, with transaction scale increasing by about 220% year-on-year[13]. - The company is focusing on the POCT auxiliary diagnosis market, launching various instant testing devices tailored for primary healthcare institutions[16]. - The company has launched a logistics platform to monitor the entire process of vehicle loading, transportation, and delivery, improving service efficiency[32]. Operational Efficiency - The company's order fulfillment efficiency improved, with same-day delivery orders increasing from 58.6% to 68.9% compared to the same period last year[12]. - The average warehouse processing time was completed within approximately 3 hours, with inter-provincial delivery taking about 38 hours to cities and 49 hours to towns[32]. - The unit fulfillment cost for self-operated same-city delivery decreased by 12.87%, while the proportion of orders delivered within half a day increased from 58.6% in 2023 to 68.9% in 2024[32]. - The return rate decreased from 0.5% in the previous year to 0.4% during the reporting period, reflecting strict quality control measures[34]. Strategic Initiatives - The company is advancing its digital transformation strategy, integrating AI and big data analytics to enhance system efficiency and user satisfaction[16]. - The company aims to strengthen its existing platform and proprietary business in the outpatient pharmaceutical industry, leveraging AI technology for service quality enhancement[19]. - The company is focusing on digital transformation and enhancing user experience through data-driven insights and service optimization[24]. - The company plans to enhance its supply chain capabilities and expand its spectrum cloud testing services[125]. Corporate Governance and Compliance - The board of directors is committed to achieving high standards of corporate governance to protect shareholder interests and enhance corporate value[109]. - The audit committee has reviewed the consolidated financial statements for the year ending December 31, 2024, and discussed accounting policies and internal controls with the management[115]. - The company has complied with the corporate governance code and has not deviated from the recommended practices, except for the dual role of the chairman and CEO[111]. Future Outlook - Looking ahead to 2025, the company aims to strengthen its existing platform and proprietary business in the outpatient pharmaceutical industry, leveraging AI technology for service quality enhancement[19]. - The company plans to optimize its product supply system and continuously expand its product categories, introducing more quality and innovative pharmaceutical products and health services[61]. - The company aims to actively promote investments and acquisitions in the industry chain to inject new momentum into long-term development and achieve strategic upgrades towards ecosystem and diversification[66].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責 任。 張步鎮先生 香 港，2025年3月5日 於 本 公 告 日 期，董 事 會 成 員 包 括 執 行 董 事 張 步 鎮 先 生 及 陳 飛 先 生，非 執 行 董 事 朱 梓 陽 先 生，以 及 獨 立 非 執 行 董 事 邵 蓉 女 士、孫 含 暉 先 生 及 趙 宏 強 先 生。 YSB Inc. 藥師幫股份有限公司 承董事會命 藥師幫股份有限公司 主席兼執行董事 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：9885） 董事會會議通告 藥師幫股份有限公司（「本公司」連同其附屬公司及綜合聯屬實體（「本集團」））董 事（「董 事」）會（「董事會」）兹通告謹定於2025年3月17日（星 期 一）舉 行 董 事 會 會 議， 以（其 中 包 括）考慮及批准本集團截至2024年12月31日止年度之年度業績及其發 佈，及 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責 任。 YSB Inc. 藥師幫股份有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：9885） 正面盈利預警 本公告乃由藥師幫股份有限公司（「本公司」，與 其 附 屬 公 司 合 稱「本集團」）根 據 《香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市 規 則》（「《上市規則》」）第13.09(2)(a)條及香港 法例第571章《證 券 及 期 貨 條 例》第XIVA部項下的內幕消息條文（定 義 見《上 市 規 則》）作 出。 本公司董事（「董 事」）會（「董事會」）謹此知會其股東（「股 東」）及 潛 在 投 資 者，基 於 對本集團截至2024年12月31日止年度（「報告期」）的未經審計綜合管理賬目及董 事 會 現 時 可 得 其 他 資 料 的 初 步 審 閱，於 報 告 期，預 期 截 至2024年1 ...

YSB Inc. 藥師幫股份有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：9885） 有關涉及根據一般授權發行對價股份的 目標公司收購事項的最新資料 茲提述藥師幫股份有限公司（「本公司」，與 其 附 屬 公 司 及 綜 合 聯 屬 實 體 合 稱「本 集 團」）日期為2024年10月15日、2024年10月28日 及2024年11月26日的公告（「該 等 公 告」），內 容 有 關（其 中 包 括）涉及根據一般授權發行對價股份的目標公司收購 事 項。除 另 有 說 明 者 外，本 公 告 所 用 詞 彙 與 該 等 公 告 所 界 定 者 具 相 同 涵 義。 董 事 會 欣 然 提 供 以 下 有 關 收 購 事 項 及 目 標 集 團 最 新 狀 況 的 最 新 資 料： 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責 任。 本公司正在落實本集團截至202 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責 任。 YSB Inc. 藥師幫股份有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：9885） 自願性公告 就股份激勵計劃購回股份 此公告乃藥師幫股份有限公司（「本公司」，與 其 附 屬 公 司 及 綜 合 聯 屬 實 體 合 稱 「本集團」）自 願 作 出。 藥師幫股份有限公司 主席兼執行董事 張步鎮先生 香 港，2025年1月13日 於 本 公 告 日 期，董 事 會 成 員 包 括 執 行 董 事 張 步 鎮 先 生 及 陳 飛 先 生，非 執 行 董 事 朱 梓 陽 先 生，以 及 獨 立 非 執 行 董 事 邵 蓉 女 士、孫 含 暉 先 生 及 趙 宏 強 先 生。 – 2 – 茲提述本公司於2023年6月12日採納的2023年股份激勵計劃（「股份激勵計劃」）， 主要條款概要載於本公司日期為2023年6月 ...